Lake Street Advisors Group LLC Has $743,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Lake Street Advisors Group LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 24.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,998 shares of the biopharmaceutical company’s stock after selling 9,023 shares during the period. Lake Street Advisors Group LLC’s holdings in Pfizer were worth $743,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Swedbank AB increased its stake in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after purchasing an additional 37,636 shares during the last quarter. Pallas Capital Advisors LLC increased its position in Pfizer by 54.8% during the third quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock worth $736,000 after buying an additional 9,102 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Pfizer by 132.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 20,361 shares of the biopharmaceutical company’s stock valued at $589,000 after buying an additional 11,615 shares in the last quarter. Integrated Advisors Network LLC lifted its position in shares of Pfizer by 18.3% in the third quarter. Integrated Advisors Network LLC now owns 64,014 shares of the biopharmaceutical company’s stock worth $1,853,000 after buying an additional 9,925 shares during the last quarter. Finally, Fidelis Capital Partners LLC lifted its position in shares of Pfizer by 5.2% in the third quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock worth $746,000 after buying an additional 1,267 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PFE. Guggenheim reissued a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Down 1.3 %

PFE stock opened at $26.40 on Thursday. The business’s 50-day simple moving average is $26.34 and its 200 day simple moving average is $27.36. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $149.63 billion, a PE ratio of 18.73, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.51%. Pfizer’s dividend payout ratio is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.